Kokorelis Christina, Gonzalez-Fernandez Marlis, Morgan Marjorie, Sadowsky Cristina
1Kennedy Krieger Institute, 707 N. Broadway, Baltimore, MD 21205 USA.
2Johns Hopkins University, 600 N. Wolfe St., Baltimore, MD 21287 USA.
Spinal Cord Ser Cases. 2019 Jan 16;5:3. doi: 10.1038/s41394-018-0146-8. eCollection 2019.
This study is a retrospective review examining the prevalence of drugs commonly used in the management of spinal cord injury (SCI) which may influence bone health.
The aim of our study was to examine the role commonly prescribed medications play in post-SCI bone health.
We included all males 21 years of age and older who were evaluated over a 10-year period at an SCI-specialized center for a trauma-induced SCI.
We compared characteristics of individuals with normal bone mass to those with low bone mass according to their dual-energy X-ray absorptiometry (DXA) scan. Medication lists were reviewed for the presence of drugs considered to either positively or negatively affect bone metabolism.
Comparing individuals with normal bone mass ( = 68) to those with low bone mass ( = 211), only "Time after Injury" and "Level of Injury" were found to influence the likelihood of having low bone mass. Multivariate analysis failed to demonstrate significant associations between bone mass and the sum of drugs which either positively or negatively affect bone metabolism. When medications were reviewed individually, only bisphosphonates and anticonvulsants were found to be significantly associated with bone mass.
Although 76% of our cohort was found to have low bone mass, the only major risk factors were "Time after Injury" and "Level of Injury". Anticonvulsant use was more common in individuals with low bone mass compared to those with normal bone mass. Given the retrospective methodology of this work, our findings underline associations that warrant further investigation.
本研究是一项回顾性分析,旨在调查脊髓损伤(SCI)管理中常用的可能影响骨骼健康的药物的使用情况。
我们研究的目的是探讨常用药物在SCI后骨骼健康中的作用。
我们纳入了所有21岁及以上的男性,他们在一家SCI专科中心接受了为期10年的创伤性SCI评估。
根据双能X线吸收法(DXA)扫描结果,我们将骨量正常的个体与骨量低的个体的特征进行了比较。审查用药清单,以确定是否存在被认为对骨代谢有正面或负面影响的药物。
将骨量正常的个体(n = 68)与骨量低的个体(n = 211)进行比较,发现只有“受伤时间”和“损伤平面”会影响骨量低的可能性。多变量分析未能证明骨量与对骨代谢有正面或负面影响的药物总和之间存在显著关联。单独审查药物时,发现只有双膦酸盐和抗惊厥药与骨量显著相关。
尽管我们队列中的76%被发现骨量低,但仅有的主要风险因素是“受伤时间”和“损伤平面”。与骨量正常的个体相比,骨量低的个体使用抗惊厥药更为常见。鉴于本研究的回顾性方法,我们的研究结果强调了值得进一步研究的关联。